Shots:
- The Japanese MHLW has granted full marketing approval to Telomelysin Injection (suratadenoturev/OBP-301) for the treatment of esophageal cancer pts ineligible for curative resection or CT, based on a Japanese pivotal trial conducted at 17 sites
- Approval triggered a milestone payment to Oncolys under its deal with FUJIFILM Toyama Chemical, which granted FUJIFILM commercialization rights to Telomelysin in Japan following NHI price listing
- Telomelysin is an oncolytic adenovirus product, which selectively replicates in the cancer cells & lyse them by utilizing telomerase activity, and is planned to be launched in Japan in 2026
Ref: Oncolys | Image: Oncolys |Press Release
Related News: Eli Lilly Receives the US FDA Approval for Ebglyss as a Q8W Maintenance Therapy for Atopic Dermatitis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
